Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


9th Indo Global Summit on Cancer Therapy

Hyderabad, India

Puneet Chandna

Puneet Chandna

AceProbe Technologies Pvt. Ltd, India

Title: Clinical decision making & prioritizing research-technological advances, judgment, experience and personalized cancer medicine


Biography: Puneet Chandna


Molecular diagnostics, personalized therapy, clinical trials, research and bioinformatics have all set precedence to the comprehensive perspectives on the current trends and treatment of cancer. The dreaded cancer disease which is analogous to the crab from the Greek mythology is considered as a class characterized by out-of-control cell growth alongside its systemic abilities to pervade, proliferate and replicate. In the current abound able stretches to treat, a clinician’s or molecular geneticists focus remains affixed to prioritize an issue that is most important from a research perspective and has actionable potential to be able to assist in moderation and superintendence of therapy, using the best available research evidence to guide clinical decision making. Traditional practice is compassionate towards the advances over the past decade in cancer treatment and emphasizes the advantage and applicability of knowledge that is continually changing the landscape of specialized, multidisciplinary personalized cancer medicine. Clinical reasoning related to diagnosis and treatment choices is evermore influenced by important transcendental elements of technology, comparison and outcomes that shape the characteristics and practice style, helping plan interventions to match the diverse needs. Moving forward, a multidisciplinary approach to answer important issues in daily practice demands frequent updates including, incidence, epidemiology, etiology and histology to combine the benefits of molecular oncology alongside current clinical and pathological findings to establish a strong legislation that could deliver and improve overall healthcare setting amidst the disparities of incidence, prevalence, modifiable risk factors to evaluate and employ new approaches to molecular diagnostics and targeted therapy in the era of personalized cancer medicine revolution which is well underway.